All
Imfinzi-Based Treatment Before, After Surgery May Significantly Improve Survival in Resectable NSCLC
March 11th 2023Patients with resectable non-small cell lung cancer treated with Imfinzi plus chemo before surgery or as monotherapy after surgery demonstrated significant improvements to event-free survival compared with those treated with neoadjuvant chemotherapy and surgery, study results show.
Chemo-Related Hearing Loss Is Common in Survivors of Testicular Cancer, Other Cancer Types
March 6th 2023With 74% of testicular cancer survivors reporting hearing loss in a recent study, one expert advised patients to advocate for themselves and their hearing before, during and after cancer treatment with cisplatin-based chemotherapy.
FDA Expands Verzenio Indication to Forego Ki-67 Score in High-Risk, Early Breast Cancer
March 6th 2023Removing the Ki-67 score to determine eligibility for Verzenio treatment in patients with HR-positive, HER2-negative, node positive, early breast cancer allows for more patients to receive this treatment.